NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIDDK E-132-2018-1-US-02 PURINE AND PYRIMIDINE NUCLEOTIDES AS ECTO-5'-NUCLEOTIDASE INHIBITORS US National Stage 17/269,094 Abandoned
CC E-228-2009-0-US-10 System And Method Of Integrated Biopsy And Therapy US CON 17/176,218 Pending
NCI E-162-2014-0-US-10 Human Monoclonal Antibodies (mAbs) Against EphA4 As Candidate Therapeutics US DIV 17/175,879 Pending
NCCIH E-081-2020-0-PCT-02 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN PCT PCT PCT/US2021/017780 Expired
NEI E-077-2018-0-US-04 METHODS OF METABOLIC REGULATION OF MITOCHONDRIA FOR
TREATING NEURAL INJURY AND NEUROLOGICAL DISORDERS 		US National Stage 17/268,203 Pending
NCI E-031-2020-0-GB-12 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION GB National Stage 2211733.7 Pending
NCI E-031-2020-0-CN-06 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION CN National Stage 202180014038.2 Pending
NCI E-031-2020-0-EP-07 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION EP National Stage 21710730.9 Pending
NCCIH E-081-2020-0-EP-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN EP National Stage 21710729.1 Pending
NCI E-031-2020-0-CA-05 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION CA National Stage 3168015 Pending
NCCIH E-081-2020-0-CA-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN CA National Stage 3167629 Pending
NCCIH E-081-2020-0-CN-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN CN National Stage 202180015900.1 Pending
NCI E-031-2020-0-CU-22 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION CU National Stage 2022-0044 Pending
NCCIH E-081-2020-0-AU-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN AU National Stage 2021220883 Pending
NIDA E-053-2016-2-AU-03 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF AU National Stage 2019340675 Pending
NCI E-031-2020-0-BR-14 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION BR National Stage BR112022015888-2 Pending
NCI E-031-2020-0-AU-04 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION AU National Stage 2021221138 Pending
NCI E-031-2020-0-TW-03 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION TW ORD 110105194 Pending
NCI E-074-2020-1-TW-02 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION TW ORD 110105193 Pending
NCCIH E-081-2020-0-MX-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN MX National Stage MX/a/2022/009914 Pending
NCCIH E-081-2020-0-JP-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN JP National Stage 2022-548411 Pending
NCCIH E-081-2020-0-NZ-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN NZ National Stage 790763 Pending
NCI E-031-2020-0-MX-19 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION MX National Stage MX/a/2022/009654 Pending
NCI E-031-2020-0-NZ-20 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION NZ National Stage 790950 Pending
NCI E-031-2020-0-JP-09 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION JP National Stage 2022-548811 Pending
NCI E-031-2020-0-US-13 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION US National Stage 17/799,163 Pending
NCI E-031-2020-0-PCT-02 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION PCT PCT PCT/US2021/017794 Expired
NCI E-074-2020-1-PCT-01 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION PCT PCT COMB PCT/US2021/017852 Expired
NCI E-031-2020-0-SG-11 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION SG National Stage 11202251837Y Pending
NCCIH E-081-2020-0-KR-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN KR National Stage 10-2022-7031665 Pending
NCI E-031-2020-0-KR-10 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION KR National Stage 2022-7031175 Pending
NCI E-031-2020-0-ZA-21 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION ZA National Stage 2022/08853 Pending
NCI E-031-2020-0-RU-23 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION RU National Stage 2022124004 Pending
NCI E-031-2020-0-IN-08 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION IN National Stage 202247050250 Pending
NIAID E-086-2020-0-PCT-02 SARS-CoV-2 VACCINE PCT PCT PCT/US2021/017709 Expired
NIAID E-086-2020-0-CN-07 SARS-CoV-2 VACCINE CN National Stage 202180027866.X Pending
NIAID E-086-2020-0-EP-08 SARS-COV-2 VACCINE EP National Stage 21710716.8 Pending
NIAID E-086-2020-0-ID-10 SARS-CoV-2 VACCINE ID National Stage P00202209715 Pending
NIAID E-086-2020-0-JP-12 SARS-CoV-2 VACCINE JP National Stage 2022-548435 Pending
NIAID E-086-2020-0-MX-14 SARS-CoV-2 VACCINE MX National Stage MX/a/2022/009836 Pending
NIAID E-086-2020-0-CA-06 SARS-CoV-2 VACCINE CA National Stage 3170322 Pending
NIAID E-086-2020-0-TH-16 SARS-CoV-2 VACCINE TH National Stage 2201005020 Pending
NIAID E-086-2020-0-BR-05 SARS-CoV-2 VACCINE BR National Stage BR112022015628-6 Pending
NIAID E-086-2020-0-AU-04 SARS-CoV-2 VACCINE AU National Stage 2021221127 Pending
NIAID E-086-2020-0-IL-11 SARS-CoV-2 VACCINE IL National Stage 295301 Pending
NIAID E-086-2020-0-ZA-15 SARS-CoV-2 VACCINE ZA National Stage 2022/08951 Pending
NIAID E-086-2020-0-KR-13 SARS-CoV-2 VACCINE KR National Stage 10-2022-7031250 Pending
NIAID E-086-2020-0-VN-17 SARS-CoV-2 VACCINE VN National Stage 1-2022-05526 Pending
NCI E-265-2015-0-AU-18 T CELL RECEPTORS RECOGNIZING HLA-CW8 RESTRICTED MUTATED KRAS` AU DIV 2021200833 Issued
NCI E-234-2014-1-KR-02 B T METHODS FOR PRODUCING AUTOLOGOUS T CELLS USEFUL TO TREAT B CELL MALIGNANCIES AND OTHER CANCERS AND COMPOSITIONS THEREOF KR DIV 10-2021-7004191 Abandoned